·糖尿病临床研究·

　　【摘要】 目的 评价厄贝沙坦与厄贝沙坦氢氯噻嗪对糖尿病合并高血压患者疗效及对血糖血脂血钾的影响。 方法 病例随机分为两组：A组(n=36)口服厄贝沙坦片(150 mg/片)，每日1片; B组(n=32)口服厄贝沙坦(150 mg)/氢氯噻嗪(12.5 mg)胶囊，每日1粒。4周后未达标者增加剂量(1片（粒）/次，2次/日)至6个月结束。 结果 降压效果B组明显优于A组(P<0.05)。两组之间治疗前后的血糖、血脂及血钾浓度均无明显差异。 结论 厄贝沙坦氢氯噻嗪比厄贝沙坦能更好地控制患者的血压，对血糖、血脂及血钾均无明显影响。

　　【关键词】 厄贝沙坦;厄贝沙坦氢氯噻嗪;糖尿病;高血压

Treatment with irbesartan and irbesartan hydrochlorothiazide for diabetics with hypertension CHU Su-ping, FU Qiong. Department of Medicine, Xingchang Hospital, Shanghai 201314, China

　　【Abstract】Objective To evaluate the effect of irbesartan and irbesartan hydrochlorothiazide on diabetics with hypertension and their impact on blood glucose, lipids, and potassium. Methods The patients were randomized into two groups: group A (n=36 ) was administered irbesartan once a day, 150mg/tablet. After 4 weeks, for those who were not reaching the target level, the dose would be increased (1 tablet, twice a day) till the end of the 6th month; and group B (n=32) was given irbesartan 150mg/tablet and hydrochlorothiazide 12.5mg/capsule, once a day. After 4 weeks, for those who were not reaching the target level, the dose would be increased (1 capsule, twice a day) till the end of the 6th month. Results The antihypertensive effect in group B was significantly better than that in group A (P<0.05). Blood glucose, lipids, and potassium concentrations before and after treatment between the two groups were not significantly different. Conclusion Comparing with irbesartan, the irbesartan hydrochlorothiazide is better in controlling the blood pressure of hypertensive diabetics without impact on blood glucose, lipids, and potassium.

　　【Key words】Irbesartan; Irbesartan hydrochlorothiazide; Diabetes mellitus; Hypertension